LOW-VOLUME · PSORIASIS

calcipotriene Side Effects

calcipotriene (also sold as Dovonex) is a LOW-VOLUME FAERS extract #420 of 524 by FAERS report count. Still opens on PSORIASIS: PSORIASIS leads at 720 reports (21.5% of the book).

Data updated 2026-05-15

3,344
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

Among 3,344 FAERS reports for calcipotriene, PSORIASIS is the most-reported reaction (720). Volume band LOW-VOLUME #420 of 524 by FAERS report count.

Thinner FAERS extract for calcipotriene (Dovonex) (3,344 reports #420 of 524 by FAERS report count). PSORIASIS leads at 720 reports (21.5% of the book). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2004–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.

PSORIASIS leads 720 of 3,344 reports

PSORIASIS
720
DIARRHOEA
210
ARTHRALGIA
199
RASH
192
NAUSEA
180
PRURITUS
170
PAIN
168
HEADACHE
157
THERAPEUTIC PRODUCT EFFECT INCOMPLETE
145
FATIGUE
141
PSORIATIC ARTHROPATHY
134
SKIN EXFOLIATION
119
TREATMENT FAILURE
117
ABDOMINAL DISCOMFORT
104
ERYTHEMA
91
CONTUSION
81

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 1,668 (53%)
Male 1,458 (47%)
Unknown 5

Age peak 45-64 (800 reports)

0-17 41 (2%)
18-44 351 (20%)
45-64 800 (46%)
65-74 329 (19%)
75+ 210 (12%)

FAERS filings rising toward 2025

2004 2025

Reactions in Death Reports

Death appears on 58 reports (1.7% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
DEATH 27
MYOCARDIAL INFARCTION 7
CARDIAC ARREST 5
ACUTE KIDNEY INJURY 4
ASTHENIA 4
CIRCULATORY COLLAPSE 4
PALPITATIONS 4
TACHYARRHYTHMIA 4
CHRONIC KIDNEY DISEASE 3
LOSS OF CONSCIOUSNESS 3
PAIN 3
ABDOMINAL PAIN 2
ACINETOBACTER INFECTION 2
ANAEMIA 2
ASCITES 2
BRADYCARDIA 2
DEHYDRATION 2
DYSPNOEA 2

Reactions in Hospitalization Reports

Hospitalization mid-share (440, 13.2%). Co-reported reactions:

Reaction Reports
CONTUSION 55
PSORIASIS 54
HYPERTENSION 52
ABDOMINAL DISCOMFORT 50
DIABETES MELLITUS INADEQUATE CONTROL 47
MOBILITY DECREASED 44
AMNESIA 42
BLOOD PRESSURE INADEQUATELY CONTROLLED 42
OEDEMA PERIPHERAL 42
COGNITIVE DISORDER 41
DEPRESSED MOOD 41
EXERCISE TOLERANCE DECREASED 41
MEDICATION ERROR 41
TREATMENT NONCOMPLIANCE 39
PERIPHERAL SWELLING 38
DYSPNOEA 35
MULTIPLE DRUG THERAPY 33
How to read calcipotriene FAERS figures (SIGNAL · DEATH-MARKED · HOSP-MID)

FAERS holds 3,344 voluntary reports linked to calcipotriene (Dovonex), 2004-2025. Death is listed on 58 (1.7%). Hospitalization appears on 440 (13.2%). Top co-reported indication: Psoriasis.

Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.

Read with calcipotriene

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.